Trends in the use of antimuscarinics and alpha-adrenergic blockers in women with lower urinary tract symptoms in Taiwan: A nationwide, population-based study, 2007-2012

Autoři: Yu-Hua Lin aff001;  Wei-Yi Huang aff004;  Chi-Chih Chang aff006;  Yu-Fen Chen aff005;  Ling-Ying Wu aff008;  Hong-Chiang Chang aff009;  Kuo-How Huang aff009
Působiště autorů: Divisions of Urology, Department of Surgery, Cardinal Tien Hospital, Taipei, Taiwan aff001;  Department of Chemistry, Fu Jen Catholic University, New Taipei City, Taiwan aff002;  Graduate Institute of Biochemical and Pharmaceutical Science, Fu Jen Catholic University, New Taipei City, Taiwan aff003;  Department of Healthcare and Medical Care, Veterans Affairs Council, Taipei, Taiwan aff004;  Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan aff005;  The Interdisciplinary Nanoscience Centre, Aarhus University, Aarhus, Denmark aff006;  Department of Nursing, Kang-Ning Junior College of Medical Care and Management, Taipei, Taiwan aff007;  Graduate Institute of European Studies, Tamkang University, Taipei, Taiwan aff008;  Department of Urology, National Taiwan University Hospital, Taipei, Taiwan aff009
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article



We aim to examine the trend in the use of antimuscarinics and off-label alpha-adrenergic blockers for treatment of lower urinary tract symptoms (LUTS) in a Taiwanese Women Cohort between 2007 and 2012.


This population-based National Health Insurance Research Database (NHIRD) was used to examine the trends in the use of antimuscarinics or off-label alpha-adrenergic blockers in Taiwan. A sample of 1,000,000 individuals randomly drawn from the whole population of 23 million individuals who were registered in the NHI in 2005. From 2007 through 2012, women aged over 18 years whose claim record contained prescriptions of either of the two drugs for treatment of any of the LUTS-related diagnoses were identified and analyzed. The annual usage of the two drug classes were calculated by defined daily dose (DDD).


From 2007–2012, there was a 0.80 fold (69676.8 to 125104.3) increase in DDD of antimuscarinics in our cohort. The overall healthcare seeking prevalence of LUTS was 7.33% in 2007 and 12.38% in 2012, in a rising trend. The prevalence of antimuscarinics-treated LUTS in our cohort increased from 2.53 in 2007 to 3.41 per 1000 women in 2012. The prevalence of LUTS treated by antimuscarinics increased especially for those older than 60 years during the study period.


This 6-year observational study provided the epidemiologic information of clinically significant LUTS of Asian female population. Moreover, there was a rising trend in the use of antimuscarinics and off-label alpha-adrenergic blockers in the population-based cohort.

Klíčová slova:

Bladder – Drug therapy – Health insurance – Incontinence – Questionnaires – Renal system – Taiwan – Alpha-adrenergic antagonist therapy


1. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14; discussion 14–5. Epub 2006/10/20. doi: 10.1016/j.eururo.2006.09.019 17049716.

2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78. Epub 2002/02/22. 11857671.

3. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs FD, Fourcade R, et al. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int. 2003;92(4):409–14. Epub 2003/08/22. doi: 10.1046/j.1464-410x.2003.04369.x 12930430.

4. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–6. Epub 2001/06/20. doi: 10.1046/j.1464-410x.2001.02228.x 11412210.

5. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36. Epub 2003/06/18. doi: 10.1007/s00345-002-0301-4 12811491.

6. Chen GD, Hu SW, Chen YC, Lin TL, Lin LY. Prevalence and correlations of anal incontinence and constipation in Taiwanese women. Neurourol Urodyn. 2003;22(7):664–9. Epub 2003/11/05. doi: 10.1002/nau.10067 14595611.

7. Lee YS, Lee KS, Jung JH, Han DH, Oh SJ, Seo JT, et al. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol. 2011;29(2):185–90. Epub 2009/11/10. doi: 10.1007/s00345-009-0490-1 19898824.

8. Wu MP, Hsu YW, Weng SF, Ho CH, Wang JJ, Tong YC. Healthcare-seeking prevalence of lower urinary tract symptoms among national health insurance enrollees in Taiwan, 2000–2009. Urology. 2013;81(1):61–5. Epub 2012/11/07. doi: 10.1016/j.urology.2012.08.033 23127798.

9. Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Piancentini A, Stewart WF, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61(6):1123–8. Epub 2003/06/18. doi: 10.1016/s0090-4295(03)00009-8 12809878.

10. Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–32, 32 e1–18. Epub 2009/12/29. doi: 10.1016/j.urology.2009.06.096 20035977.

11. Alexandre EC, de Oliveira MG, Campos R, Kiguti LR, Calmasini FB, Silva FH, et al. How important is the alpha1-adrenoceptor in primate and rodent proximal urethra? Sex differences in the contribution of alpha1-adrenoceptor to urethral contractility. Am J Physiol Renal Physiol. 2017;312(6):F1026–F34. doi: 10.1152/ajprenal.00013.2017 28298357.

12. Low BY, Liong ML, Yuen KH, Chee C, Leong WS, Chong WL, et al. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. J Urol. 2008;179(4):1461–9. doi: 10.1016/j.juro.2007.11.060 18295277.

13. Pummangura N, Kochakarn W. Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women. Asian J Surg. 2007;30(2):131–7. doi: 10.1016/S1015-9584(09)60146-9 17475584.

14. Lee KS, Han DH, Lee YS, Choo MS, Yoo TK, Park HJ, et al. Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study. J Korean Med Sci. 2010;25(1):117–22. doi: 10.3346/jkms.2010.25.1.117 20052356


16. Lee H, Jeong SJ. Epidemiology of lower urinary tract symptoms: emphasis on the status in Korea. Korean J Urol. 2014;55(5):300–8. Epub 2014/05/29. doi: 10.4111/kju.2014.55.5.300 24868333

17. Altman D, Granath F, Mattiasson A, Falconer C. Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(11):1285–91. Epub 2009/07/29. doi: 10.1007/s00192-009-0957-z 19636490.

18. Hu TW, Wagner TH. Economic considerations in overactive bladder. Am J Manag Care. 2000;6(11 Suppl):S591–8. Epub 2001/02/24. 11183902.

19. Irwin DE, Milsom I, Kopp Z, Abrams P, Group ES. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol. 2008;53(5):1029–37. Epub 2008/02/05. doi: 10.1016/j.eururo.2008.01.027 18243515.

20. Moorthy P, Lapitan MC, Quek PL, Lim PH. Prevalence of overactive bladder in Asian men: an epidemiological survey. BJU Int. 2004;93(4):528–31. Epub 2004/03/11. doi: 10.1111/j.1464-410x.2003.04682.x 15008723.

21. Wennberg AL, Molander U, Fall M, Edlund C, Peeker R, Milsom I. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Eur Urol. 2009;55(4):783–91. Epub 2009/01/23. doi: 10.1016/j.eururo.2009.01.007 19157689.

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden